Publications by authors named "A F Bolarinwa"
Article Synopsis
- There are three main types of BCMA-directed therapy for myeloma: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each offering unique benefits and challenges.
- A study at Mayo Clinic examined 339 myeloma patients treated with various BDTs from 2018 to 2023, finding that CAR-T and TCEs provided significantly better progression-free and overall survival compared to ADCs.
- Results indicated that while CAR-T is the most effective option, patients with previous BDT experiences or aggressive disease may benefit more from other treatment strategies.
Background: Sickle cell disease (SCD) refers to a group of genetic disorders characterized by the presence of an abnormal haemoglobin molecule called haemoglobin S (HbS). When subjected to oxidative stress from low oxygen concentrations, HbS molecules form rigid polymers, giving the red cell the typical sickle shape. Antioxidants have been shown to reduce oxidative stress and improve outcomes in other diseases associated with oxidative stress.
View Article and Find Full Text PDFObjectives: Hypoxia is a known feature of sickle cell anaemia (SCA) which results from chronic anaemia and recurrent vaso-occlusive crisis (VOC) which can cause tissue ischaemia that leads to an end organ damage. The hallmark of SCA is chronic anaemia and recurrent vaso-occlusive crisis. The aim of this study is to compare the oxygen saturation of sickle cell anaemic individuals with the normal haemoglobin type (Hb AA) control and also to determine the prevalence of hypoxemia among SCA.
View Article and Find Full Text PDF